| Autor: |
S. V. Villevalde, A. S. Galyavich, N. G. Vinogradova, E. N. Volodina, I. R. Gaisin, S. R. Gilyarevsky, L. V. Grekhova, Yu. A. Guryanova, P. S. Guseva, D. V. Duplyakov, A. V. Ezhov, N. E. Zakirova, Yu. V. Zolotova, A. V. Isakov, S. V. Kanysheva, Z. F. Kim, V. P. Kuzmin, S. S. Markiyanova, S. A. Pomosov, A. P. Rebrov, E. I. Tarlovskaya, S. N. Tolstov, I. V. Fomin, N. R. Khasanov, A. M. Shutov |
| Jazyk: |
ruština |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Российский кардиологический журнал, Vol 26, Iss 2S (2021) |
| ISSN: |
2618-7620
1560-4071 |
| Popis: |
An online meeting of experts held on November 6, 2020 describes the results of EMPA-REG OUTCOME and EMPEROR-Reduced trials on sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. We analyzed cardiovascular and renal outcomes in patients with and without type 2 diabetes (T2D) receiving empagliflozin. A number of proposals and recommendations have been adopted regarding the further study of the cardiovascular and renal effects of empagliflozin and its practical use in patients with heart failure, regardless of the T2D presence. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
